丝裂霉素C对HAD房水引流物置入术远期疗效的影响

目的:评价丝裂霉素 C(mitomycin C,MMC)对国产 HAD(Hunan aqueous drainage implant,HAD)房水引流物置入术治疗难治性青光眼远期疗效的影响。方法:1995年7月～2001年7月,共为154例(159只眼)难治性青光眼患者施行了HAD房水引流物置入术。所有病例分为两组:MMC组与未用MMC组,其中65只眼术中联合应用MMC(0.4mg/ml,1～5min),94只眼术中未用 MMC。以 6mmHg≤术后眼压≤21mmHg作为手术成功标准,采用Kaplan-Meier寿命表分析术后1～6a.不同时点的手术成功率。结果:术后平均随访54.6mon(12～72mon)。术前平均眼压(46.8±14.5)mmHg;术后1年时眼压为(17.4±10.1)mmHg。术后1～6a手术成功率依次为83.7%,77.2%,72.2%,69.0%,62.5%,57.1%。术后1～5a,MMC组与未用MMC组的手术成功率分别为90.0%、77.3%,87.1%、67.3%,83.3%、61.1%,81.3%、56.7%,75.0%、50.0%;两组间差异有显著性。术后1a时眼部超声图像检查,后部滤过泡的平均高度MMC组为(3.8±0.9)mm,而未用MMC组为(2.1±1.4)mm。术后视力不变或改善的有95只眼(81.9%),两组间无明显差异。术后远期(一年以上)常见的并发症有眼压升高(23例,19.8%)、引流管与周围虹膜粘连(18例,15.5%)、白内障加速形成(15例,12.9%)等,两组间无明显差异,未见MMC的严重并发症发生。结论:HAD房水

Long-term Follow-up Study on Hunan Aqueous Drainage Implantation Combined with Mitomycin C for Refractory Glaucoma

PURPOSE: To investigate the long-term therapeutic effect of Hunan aqueous drainage (HAD) implantation with and without adjunctive intraoperative mitomycin C (MMC) for refractory glaucoma. METHODS: 154 cases (159 eyes) with refractory glaucoma underwent Hunan aqueous drainage (HAD) implantation from July 1995 to July 2001. Sixty-five eyes were combined with MMC (0.4 mg/ml, 1 to 5 mins). With success defined as the introcular pressure (IOP) greater than 6 mmHg but no greater than 21 mmHg at the last visit. RESULTS: The mean period of postoperative follow-up was 54.6 (range, 12-72) months. The IOP was lowered from preoperative (46.8 +/- 14.5) mmHg to postoperative (16.8 +/- 11.3) mmHg at the 1st year after surgery. The success rate with MMC and without MMC were 90.0%, 77.3% (P < 0.05) at the 1st year, 87.1%, 67.3% (P < 0.05) at the 2nd year, 83.3%, 61.1% (P < 0.05) at the 3rd year, 81.3%, 56.7% (P < 0.05) at the 4th year, and 75.0%, 50.0% (P < 0.05) at the 5th year using Kaplan-Meier life-table analysis. The height of the posterior bleb underwent standardized ocular echography at the 1st year was (3.8 +/- 0.9) mm and (2.1 +/- 1.4) mm, respectively. Ninty-five eyes (81.9%) with visual acuity remained or improved after the surgery (P > 0.05). The most frequent complications for long-term follow-up included elevated IOP (IOP > 22 mmHg) (19.8%), the iris adherent to the proximal orifice of the tube (15.5%), developed cataract formation (12.9%) and so on (P > 0.05). We didn't find any severe complications after using MMC. CONCLUSION: This study suggests that HAD implantation is an effective method in the management of refractory glaucoma in spite of its unneligible complications and combined with MMC can improve the prognosis.